Drug Survival of Tumor Necrosis Factor-Alpha Inhibitors and Switched Subsequent Biologic Agents in Patients with Psoriasis: A Retrospective Study
Abstract Introduction This study aimed to retrospectively examine the drug survival of tumor necrosis factor (TNF)-alpha inhibitors and switched subsequent biologic agents after discontinuation of TNF inhibitors. Methods This real-world setting study was conducted at a single academic center. We inc...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2023-05-01
|
| Series: | Dermatology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s13555-023-00932-0 |
| _version_ | 1797801580287754240 |
|---|---|
| author | Megumi Kishimoto Mayumi Komine Koji Kamiya Junichi Sugai Aya Kuwahara Makiko Mieno Mamitaro Ohtsuki |
| author_facet | Megumi Kishimoto Mayumi Komine Koji Kamiya Junichi Sugai Aya Kuwahara Makiko Mieno Mamitaro Ohtsuki |
| author_sort | Megumi Kishimoto |
| collection | DOAJ |
| description | Abstract Introduction This study aimed to retrospectively examine the drug survival of tumor necrosis factor (TNF)-alpha inhibitors and switched subsequent biologic agents after discontinuation of TNF inhibitors. Methods This real-world setting study was conducted at a single academic center. We included patients who were treated with adalimumab (n = 111), certolizumab pegol (n = 12), and infliximab (n = 74) at Jichi Medical University Hospital from 1 January 2010 to 31 July 2021. Results No significant differences were noted in drug survival between the three TNF inhibitors. The 10-year drug survival rate for adalimumab and infliximab was 14% and 18%, respectively. Of the patients who discontinued TNF inhibitors for any reason (n = 137), 105 chose biologics as their subsequent treatment. The subsequent biologics included 31 cases of TNF inhibitors (adalimumab in 20, certolizumab pegol in 1, and infliximab in 10), 19 of interleukin-12/23 inhibitor (ustekinumab), 42 of interleukin-17 inhibitors (secukinumab in 19, brodalumab in 9, and ixekizumab in 14) and 13 of interleukin-23 inhibitors (guselkumab in 11, risankizumab in 1, and tildrakizumab in 1). Cox proportional hazards analysis for the subsequent drugs in cases of discontinuation due to inadequate efficacy revealed that female sex was a predictor of drug discontinuation (hazard ratio 2.58, 95% confidence interval 1.17–5.70) and that taking interleukin-17 inhibitors rather than TNF inhibitors was a predictor of drug persistence (hazard ratio 0.37, 95% confidence interval 0.15–0.93). Conclusions Interleukin-17 inhibitors may be a favorable option for patients who need to switch from TNF inhibitors due to inadequate efficacy. However, this study is limited by the small number of cases and its retrospective design. |
| first_indexed | 2024-03-13T04:52:54Z |
| format | Article |
| id | doaj.art-887e69b2209d4ab787684aca16a0167e |
| institution | Directory Open Access Journal |
| issn | 2193-8210 2190-9172 |
| language | English |
| last_indexed | 2024-03-13T04:52:54Z |
| publishDate | 2023-05-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Dermatology and Therapy |
| spelling | doaj.art-887e69b2209d4ab787684aca16a0167e2023-06-18T11:07:10ZengAdis, Springer HealthcareDermatology and Therapy2193-82102190-91722023-05-011361347136010.1007/s13555-023-00932-0Drug Survival of Tumor Necrosis Factor-Alpha Inhibitors and Switched Subsequent Biologic Agents in Patients with Psoriasis: A Retrospective StudyMegumi Kishimoto0Mayumi Komine1Koji Kamiya2Junichi Sugai3Aya Kuwahara4Makiko Mieno5Mamitaro Ohtsuki6Department of Dermatology, Jichi Medical UniversityDepartment of Dermatology, Jichi Medical UniversityDepartment of Dermatology, Jichi Medical UniversityDepartment of Dermatology, Jichi Medical UniversityDepartment of Dermatology, Jichi Medical UniversityDepartment of Medical Informatics, Center for Information, Jichi Medical UniversityDepartment of Dermatology, Jichi Medical UniversityAbstract Introduction This study aimed to retrospectively examine the drug survival of tumor necrosis factor (TNF)-alpha inhibitors and switched subsequent biologic agents after discontinuation of TNF inhibitors. Methods This real-world setting study was conducted at a single academic center. We included patients who were treated with adalimumab (n = 111), certolizumab pegol (n = 12), and infliximab (n = 74) at Jichi Medical University Hospital from 1 January 2010 to 31 July 2021. Results No significant differences were noted in drug survival between the three TNF inhibitors. The 10-year drug survival rate for adalimumab and infliximab was 14% and 18%, respectively. Of the patients who discontinued TNF inhibitors for any reason (n = 137), 105 chose biologics as their subsequent treatment. The subsequent biologics included 31 cases of TNF inhibitors (adalimumab in 20, certolizumab pegol in 1, and infliximab in 10), 19 of interleukin-12/23 inhibitor (ustekinumab), 42 of interleukin-17 inhibitors (secukinumab in 19, brodalumab in 9, and ixekizumab in 14) and 13 of interleukin-23 inhibitors (guselkumab in 11, risankizumab in 1, and tildrakizumab in 1). Cox proportional hazards analysis for the subsequent drugs in cases of discontinuation due to inadequate efficacy revealed that female sex was a predictor of drug discontinuation (hazard ratio 2.58, 95% confidence interval 1.17–5.70) and that taking interleukin-17 inhibitors rather than TNF inhibitors was a predictor of drug persistence (hazard ratio 0.37, 95% confidence interval 0.15–0.93). Conclusions Interleukin-17 inhibitors may be a favorable option for patients who need to switch from TNF inhibitors due to inadequate efficacy. However, this study is limited by the small number of cases and its retrospective design.https://doi.org/10.1007/s13555-023-00932-0AdalimumabBiologicsCertolizumab pegolDrug switchingInfliximabKaplan–Meier survival curves |
| spellingShingle | Megumi Kishimoto Mayumi Komine Koji Kamiya Junichi Sugai Aya Kuwahara Makiko Mieno Mamitaro Ohtsuki Drug Survival of Tumor Necrosis Factor-Alpha Inhibitors and Switched Subsequent Biologic Agents in Patients with Psoriasis: A Retrospective Study Dermatology and Therapy Adalimumab Biologics Certolizumab pegol Drug switching Infliximab Kaplan–Meier survival curves |
| title | Drug Survival of Tumor Necrosis Factor-Alpha Inhibitors and Switched Subsequent Biologic Agents in Patients with Psoriasis: A Retrospective Study |
| title_full | Drug Survival of Tumor Necrosis Factor-Alpha Inhibitors and Switched Subsequent Biologic Agents in Patients with Psoriasis: A Retrospective Study |
| title_fullStr | Drug Survival of Tumor Necrosis Factor-Alpha Inhibitors and Switched Subsequent Biologic Agents in Patients with Psoriasis: A Retrospective Study |
| title_full_unstemmed | Drug Survival of Tumor Necrosis Factor-Alpha Inhibitors and Switched Subsequent Biologic Agents in Patients with Psoriasis: A Retrospective Study |
| title_short | Drug Survival of Tumor Necrosis Factor-Alpha Inhibitors and Switched Subsequent Biologic Agents in Patients with Psoriasis: A Retrospective Study |
| title_sort | drug survival of tumor necrosis factor alpha inhibitors and switched subsequent biologic agents in patients with psoriasis a retrospective study |
| topic | Adalimumab Biologics Certolizumab pegol Drug switching Infliximab Kaplan–Meier survival curves |
| url | https://doi.org/10.1007/s13555-023-00932-0 |
| work_keys_str_mv | AT megumikishimoto drugsurvivaloftumornecrosisfactoralphainhibitorsandswitchedsubsequentbiologicagentsinpatientswithpsoriasisaretrospectivestudy AT mayumikomine drugsurvivaloftumornecrosisfactoralphainhibitorsandswitchedsubsequentbiologicagentsinpatientswithpsoriasisaretrospectivestudy AT kojikamiya drugsurvivaloftumornecrosisfactoralphainhibitorsandswitchedsubsequentbiologicagentsinpatientswithpsoriasisaretrospectivestudy AT junichisugai drugsurvivaloftumornecrosisfactoralphainhibitorsandswitchedsubsequentbiologicagentsinpatientswithpsoriasisaretrospectivestudy AT ayakuwahara drugsurvivaloftumornecrosisfactoralphainhibitorsandswitchedsubsequentbiologicagentsinpatientswithpsoriasisaretrospectivestudy AT makikomieno drugsurvivaloftumornecrosisfactoralphainhibitorsandswitchedsubsequentbiologicagentsinpatientswithpsoriasisaretrospectivestudy AT mamitaroohtsuki drugsurvivaloftumornecrosisfactoralphainhibitorsandswitchedsubsequentbiologicagentsinpatientswithpsoriasisaretrospectivestudy |